ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)
March 02 2022 - 6:33AM
Business Wire
New Phase I research showcases NR
supplementation significantly increased cerebral NAD levels, and
decreased levels of inflammatory cytokines in Parkinson’s disease
(PD) patients
ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings
from a first-of-its-kind clinical study, as reported in the
peer-reviewed journal Cell Metabolism by a team of scientists led
by Prof. Charalampos Tzoulis, Haukeland University Hospital and
University of Bergen, in Norway. The clinical trial was part of the
ChromaDex External Research Program (CERP™) and investigated the
company’s proprietary Niagen® ingredient (patented nicotinamide
riboside, or “NR”) in patients with Parkinson’s disease (PD).
Results of the phase I clinical trial showed that NR
supplementation significantly increased cerebral nicotinamide
adenine dinucleotide (NAD) levels, and resulted in altered cerebral
energy metabolism and decreased levels of inflammatory cytokines in
patients with PD. This clinical study is a milestone in NR and PD
research and builds upon previous preclinical studies exploring the
positive impact of NR on neurodegenerative diseases.
Parkinson’s disease is a common neurodegenerative disorder,
affecting more than 10 million people worldwide. It is largely
characterized by progressive impairments in motor function,
including tremor, stiffness, slow movement, and poor balance, as
well as in non-motor functions, such as abnormal sleep patterns,
gastrointestinal dysfunction, and cognitive impairment, or
dementia. Abnormal energy metabolism due to dysfunction in the
mitochondria, the powerhouses of the cell, has been linked to PD
and is believed to play a role in the initiation and progression of
the disease. As such, this study assessed NR as a potential
therapeutic strategy targeting mitochondrial function and energy
metabolism in PD patients.
“The results of this phase I study in humans are an encouraging
step forward for Parkinson’s research and a potentially promising
alternative for PD therapy,” said Dr. Andrew Shao, ChromaDex Senior
Vice President of Global Scientific & Regulatory Affairs. “We
look forward to further research aimed at understanding the role of
NR supplementation in Parkinson’s patients.”
“We are very excited about these results,” said Prof.
Charalampos Tzoulis, Professor of Neurology and Neurogenetics,
Director of the K.G Jebsen Center for Translational Research in
Parkinson’s disease, and Co-Director of the Neuro-SysMed Research
Center, University of Bergen and Haukeland University Hospital,
Bergen, Norway. “This trial represents a novel approach in
experimental PD-therapy. We believe that augmenting the brain’s NAD
metabolism will not only target and rectify disease-related
processes specific to PD, but may also optimize neuronal metabolism
and fortify neurons, rendering them more resilient against
age-related stress and neurodegenerative diseases. The results of
the trial are highly encouraging and nominate NR as a potential
neuroprotective therapy for PD, warranting further investigation in
larger trials. A phase II study is already ongoing at our Center,
and estimated to conclude by the end of 2023.” The phase II NO-PARK
study will feature NAD supplementation in 400 PD patients for one
full year. Public information on this study can be viewed here:
https://neuro-sysmed.no/dis-clinic-stud/parkinsons-disease/ and at
www.clinicaltrials.gov.
This randomized, double-blinded, placebo-controlled human phase
I clinical study featured 30 newly diagnosed patients with PD who
never received dopamine therapy (a standard treatment used to treat
motor symptoms in PD patients). The patients were randomized into
two groups - one group was provided 1000mg/day of NR and the other
a placebo. Clinical, neuroimaging and molecular measures were used
to assess all patients at baseline and after 30 days of
exposure.
The results of the study demonstrated that NR-recipient patients
showed significantly increased brain NAD levels, an altered brain
metabolic pattern, and decreased levels of inflammatory cytokines
in the cerebrospinal fluid. Moreover, patients experienced a mild
but significant clinical improvement, and this correlated with the
change in the brain’s metabolic pattern.
“These findings, particularly the effects on pro-inflammatory
cytokines and clinical symptoms, are clearly supportive of carrying
out larger trials in Parkinson disease patients," said Dr. Rudolph
Tanzi, Vice Chair of Neurology and Co-Director of McCance Center
for Brain Health at Massachusetts General Hospital, Joseph P. and
Rose F. Kennedy Professor of Neurology at Harvard Medical School,
and member of the ChromaDex Scientific Advisory Board.
These promising results suggest that NR supplementation may have
neuroprotective potential by targeting various processes implicated
in the development of PD, however further research needs to be
conducted on its use as a potential therapeutic strategy.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to results of the
pre-clinical and clinical NR studies, their significance and the
potential of NR as a promising alternative for PD therapy.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220302005311/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024